Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alimera Sciences Inc ALIM

Healthcare
Alimera Sciences, Inc. is a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic retinal pharmaceuticals. It is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for non-infectious uveitis affecting the posterior segment of the eye ... see more

Recent & Breaking News (NDAQ:ALIM)

Alimera Sciences Limited Announces ILUVIEN® Study Results Presented At 15th Euretina Congress

PR Newswire September 24, 2015

Alimera Sciences Limited Signs Exclusive ILUVIEN® Distributor for Italy, San Marino and Vatican City

PR Newswire August 13, 2015

Alimera Sciences Reports Second Quarter 2015 Financial Results

PR Newswire August 10, 2015

Alimera Sciences To Release Second Quarter Fiscal Year 2015 Financial Results

PR Newswire July 30, 2015

Alimera Sciences Signs Knight Therapeutics As Exclusive ILUVIEN® Distributor For Canada

PR Newswire July 21, 2015

Alimera Sciences To Present At Cantor Fitzgerald Inaugural Healthcare Conference

PR Newswire June 29, 2015

Alimera Sciences Announces Presentation Time Change At UBS Global Healthcare Conference

PR Newswire May 18, 2015

Alimera Sciences To Present At UBS Global Healthcare Conference

PR Newswire May 11, 2015

Alimera Sciences Reports First Quarter 2015 Financial Results

PR Newswire May 7, 2015

Alimera Sciences to Release First Quarter 2015 Financial Results

PR Newswire April 28, 2015

ILUVIEN® Is Now Widely Available To Diabetic Macular Edema Patients Throughout The U.S.

PR Newswire April 21, 2015

Alimera Sciences' ILUVIEN® Receives 17th European Marketing Authorization; Completing Second Wave Of Country Approvals

PR Newswire April 14, 2015

Alimera Sciences to Host Analyst and Investor Luncheon on Wednesday, March 25, 2015 in New York City

PR Newswire March 19, 2015

Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results

PR Newswire March 4, 2015

Alimera Sciences To Release Fourth Quarter And Fiscal Year 2014 Financial Results

PR Newswire February 23, 2015

Alimera Sciences To Present At 2015 Cowen Healthcare Conference

PR Newswire February 23, 2015

Alimera Sciences To Host ILUVIEN® Live Webinar Launch Event

PR Newswire February 17, 2015

Alimera Sciences' ILUVIEN® Receives Marketing Authorization in Finland and Luxembourg

PR Newswire January 26, 2015

Alimera Sciences Announces First Sale of ILUVIEN® in Portugal

PR Newswire January 14, 2015

Alimera Sciences Added to NASDAQ Biotechnology Index

PR Newswire December 16, 2014